Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Connecting Arizonans to Coverage (CA2C) | Cooperative Agreement | $221,000.00 | Other Sponsored Activity | Marc Verhougstraete | Community Environment & Policy | Arizona Alliance for Community Health Centers | 01/2022 |
| BRACE: Implementation and Evaluation | Grant | $450,000.00 | Other Sponsored Activity | Heidi Brown | Epidemiology and Biostatistics | Arizona Department of Health Services | 01/2022 |
| Study Using Negative Pressure to Reduce Apnea (SUPRA) | Contract | $166,386.00 | Clinical Trial | Sairam Parthasarathy | Medicine | Sommetrics, Inc | 01/2022 |
| An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH | Contract | $447,126.32 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 01/2022 |
| A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13 to 17 year-old Autism Spectrum Disorder Population | Contract | $189,110.48 | Clinical Trial | Sydney Rice | Pediatrics | Axial Therapeutics, Inc. | 01/2022 |
| A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RAPRO PRagmatic Trial (RA-PROPR) | Contract | $35,112.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | University of Alabama at Birmingham | 01/2022 |
| A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV Infections in Imm | Contract | $207,283.75 | Clinical Trial | Tirdad Zangeneh | Medicine | AiCuris Anti-Infective Cures (Germany) | 01/2022 |
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplast | Contract | $109,845.08 | Clinical Trial | Sharad Khurana | Cancer Center Division | Syros Pharmaceuticals, Inc | 01/2022 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aur | Contract | $82,971.76 | Clinical Trial | Tanya Anand | Surgery | ContraFect Corp | 01/2022 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy fo | Contract | $989,638.00 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 01/2022 |
| A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and N | Contract | $251,744.40 | Clinical Trial | Ricklie Julian | Cancer Center Division | Astrazeneca | 01/2022 |
| A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at High-risk for Developing Allergic Disease | Contract | $125,377.52 | Clinical Trial | Heather Cassell | Asthma/Airway Disease Rsch Ctr | Siolta Therapeutics | 01/2022 |
| A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refr | Contract | $1,799,212.70 | Clinical Trial | Muhammad Husnain | Cancer Center Division | AbbVie Incorporated | 01/2022 |
| A Phase 1a/B Study to Evaluate the Safety and Tolerability of Etc-1922159 in Advanced Solid Tumours | Contract | $364,303.75 | Clinical Trial | Aaron Scott | Cancer Center Division | PPD Investigator Services, LLC. | 01/2022 |
| A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated.. | Contract | $3,170,000.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | Albert Einstein College of Medicine | 01/2022 |
| The Effect of Opioids on Fracture Healing | Gift | $460.50 | Research Training | David Margolis | Orthopedic Surgery | Arizona State University | 12/2021 |
| Studies on the Interaction Between Piezo1 and TRPV4 Channel in Lens Epithelium (WAESO) | Grant | $614.00 | Research Training | Mohammad Shahidullah | Physiology | Arizona State University | 12/2021 |
| Quantitative Histomorphometry of Implanted Composite Ceramic Polymer Scaffolds | Grant | $460.50 | Research Training | David Margolis | Orthopedic Surgery | Arizona State University | 12/2021 |
| PCR Analysis of Human and Animal Cells for Tissue Regeneration -WAESO Fall 2021 | Grant | $460.50 | Research Training | John Szivek | Orthopedic Surgery | Arizona State University | 12/2021 |
| Deciphering Oncogenic Contributions of Atopobium/Fannyhessea Species to Understand Gynecologic Cancer Utilizing Multi-omic Approaches and 3-D Human Cell Models. | Grant | $48,500.00 | Research Training | Nicole Jimenez | COM Phx Obstetrics&Gynecology | University of Arizona Foundation | 12/2021 |
| Compression Testing of Composite Ceramic Polymer Materials | Grant | $460.50 | Research Training | David Margolis | Orthopedic Surgery | Arizona State University | 12/2021 |
| Combining Hydrogel Cell Printing with Thermoplastic 3D Printing | Grant | $460.50 | Research Training | David Margolis | Orthopedic Surgery | Arizona State University | 12/2021 |
| Exposure Assessment and Risk Impact of Air Dryers | Contract | $76,997.00 | Research - Industry (62.5% MTDC) | Kelly Reynolds | Community Environment & Policy | Excel Dryer, Inc. | 12/2021 |
| Blood-Brain Barrier Permeability and Microglia Targeting of Novel Neurotherapeutics | Contract | $103,855.00 | Research - Industry (62.5% MTDC) | Patrick Ronaldson | Pharmacology | Vigil Neuroscience, Inc. | 12/2021 |
| A Phase I Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza in Healthy Individuals | Contract | $85,313.00 | Research - Industry (62.5% MTDC) | Carol Gregorio | Cellular & Molecular Medicine | Pfizer, Incorporated | 12/2021 |